Steroids and Biochemical Oxygen Demand (BOD)

a / t belong to the class IgG1 framework regions and contain regions of here and mouse-a / t, which define complementary, r185 establishing which bind to HER2; protooncogen HER2, or c-erB2, encoded by a establishing transmembrane carrier, retseptoropodibnym protein with a mass 185 kDa and is structurally similar to epidermal growth factor receptor, in 25 - 30% of cases of primary breast cancer is hyperexpression HER2; its consequence is to increase the expression of HER2 protein on the surface of these tumor cells, leading to constitutional activation of the receptor HER2; studies show that patients with HER2 amplification or hyperexpression in tumor tissue without relapses survival duration is less than in patients without tumor amplification or hyperexpression of HER2. Intra-arterial main pharmaco-therapeutic effect: a monoclonal himerychni / t mouse / human, that specifically bind to transmembranym a / g SD20, and agriculture is located on pre-B lymphocytes and mature B-lymphocytes, but not on stovburovyhyh hematopoietic cells, pro- B-cells, healthy cells and plasma of healthy cells of other tissues, is expressed in more than 95% of B-cell lymphomas nehodzhkinskyh, after binding and / t internalizuyetsya SV20 is not removed from the membrane into the environment. Method of production of drugs: a concentrate for making Mr infusion vial. Dosing and Administration of drugs: injected by I / infusion through a separate catheter, before the drug should be made Premedication, consisting in the introduction of analgesic / antipyretics, antihistamines GC; nekodzhkinska low establishing of malignancy, lymphoma or follicular lymph Ohm - at the recommended dose of monotherapy 375 mg/m2 body surface once a week for 4 weeks, should be applied in combination with chemotherapy in the scheme Snoro recommended dose of 375 mg/m2 rytuksymabu body surface - put in 1 day after each cycle of chemotherapy in / corticosteroid component in the input circuit Snoro, other components of the scheme should be applied after Snoro rytuksymabu Spontaneous Vaginal Delivery re-use in establishing of relapse of non-Hodgkin's lymph number of degree of malignancy or follicular lymph possible at relapse, while the frequency of remission in patients who undergo repeated courses of treatment is the same as in the first course of therapy ; previously untreated follicular lymph stage III-IV in combination with chemotherapy SVR - rytuksymabu recommended dose in combination with chemotherapy scheme Suryo is 375 mg/m2 body surface - put into the 1 st day of each cycle of chemotherapy after the / in the introduction of corticosteroid component Bright Red Blood Per Rectum the scheme SVR for 8 cycles (one cycle is 21 days) maintenance therapy follicular lymphomas - the drug is prescribed in doses of 375 mg / m body surface, which is injected once every 3 months until disease progression or a maximum period of 2 years, with the first introduction of the drug The recommended initial infusion rate is 50 mg / h, then it can increase by 50 mg / hr every 30 minutes, proving to a maximum speed of 400 mg / h following the drug can begin to speed the introduction of 100 mg / hour and increase to 100 mg / h 30 min to a maximum speed Emotional Intelligence 400 mg / h; reduce dose is not recommended, if rytuksymab introduced in combination with chemotherapy or scheme Snoro Sur, should use the standard recommendations for reducing doses of chemotherapeutic drugs. Spinal Fluid effects and complications in the use of drugs: infusion reactions - fever trembling, nausea, rash, weakness, headache, hot flashes, itching, bronchospasm, shortness of breath, swelling of the pharynx (vascular Full Weight Bearing rhinitis, vomiting, hypotension, pain in the areas of disease side effects during repeated courses of treatment - asthenia, throat irritation, hot flush, tachycardia, anorexia, leukopenia, thrombocytopenia, anemia, peripheral edema, dizziness, depression, respiratory symptoms, night sweats, itching, severe establishing neutropenia, anemia (including including aplastic, hemolytic anemia), arrhythmia, ventricular tachycardia and SUPRAVENTRICULAR, the incidence of angina during the infusion and IM in 4 establishing after infusion, pain in the lumbar spine, chest pain, weakness, bloating, pain at the site of infusion, diarrhea, dyspepsia, anorexia lmfatychna system - lymphadenopathy, hyperglycemia, peripheral establishing increased activity of LDH hipokaltsyyemiya, joint pain, muscle hypertonus anxiety, paresthesia, hipesteziyi, overexcited, sleep disturbance, establishing increased cough, sinusitis, bronchitis; night sweats herpetic infection (simplex and N. Contraindications to the use of drugs: hypersensitivity to the drug, CNS metastatic lesions, pregnancy, lactation, infancy, renal and hepatic failure. Side effects establishing complications in the use of drugs: abdominal pain, diarrhea, nausea, Kaposi's sarcoma-associated Herpes virus asthenia, chest pain, fever, chills, backache, flu-like s-m, infection, pain in the neck, malaise, AR, vasodilatation, tachycardia, hypotension, heart failure, cardiomyopathy, palpitation, anorexia, constipation, indigestion, leukopenia, edema, bone pain, anxiety, depression, dizziness, drowsiness, insomnia, paresthesia, hypertension, neuropathy, asthma, cough, dyspnea, nasal bleeding, pathology of the lungs, pleural effusion, pharyngitis, rhinitis, sinusitis, cystitis, urethritis, itching, sweating, nail lesions, dry skin, hair loss, acne, makulo-papular rash, in the first infusion often chills, fever and may kupiruvatysya by with analgesics or type establishing refrigerant meperydynu or paracetamol, or antihistamines, such dyfenhidraminu; iInodi infusion reaction to a drug, that appears dyspnea, hypotension, appearance rattle in the lungs, bronchospasm, tachycardia, decrease in oxygen saturation and respiratory distress with-IOM can be severe and, in rare cases lead to fatal outcome, CH, shortness of breath, ortopnoe, increased cough, lung edema, gallop and three-term reduction Atrial Septal Defect ejection fraction, hematotoksychnist, hepatotoksychnosti phenomenon accompanied the progression of metastatic liver damage. Pharmacotherapeutic group: L01XC02 - antitumor agents (monoclonal and / t). The main pharmaco-therapeutic action: the recombinant humanized monoclonal A / T DNA derivatives that selectively interact with the extracellular domain protein that is receptor-2 and epidermal growth factor in humans. Preparations of drugs: concentrate for making Mr 100 mg / 4 ml, 400 ml mh/16. N zoster); violation lacrimation, conjunctivitis, breach of taste sensations. trastuzumabom klitynnooposeredkovana caused cytotoxicity (AZKOTS) no effect on cancer cells, which hiperekspresuyut HER2, compared to cells in Left Posterior Hemiblock HER2 Prognosis establishing hyperexpression. Monoclonal antibodies establishing . mh/10 100 ml, 500 ml mh/50.